Paolo Caimi, MD
Hematology & Oncology · Cleveland, OHNPI 1538291901
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $91,513 of the $113,367 with a category attached, or 80.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 15.8%. Reporting peaked in 2023 at $23,319 and has fallen 56.8% since, to $10,064 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $1245.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$18K
- Genentech, Inc.$14K
- ADC Therapeutics America, Inc.$12K
- Gilead$11K
- Novartis$9K
- Amgen$6K
- plus $43K from 19 others
Across 224 payments — averaging $18,290 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.3M
- Genmab U.S., Inc.$581K
- Takeda Pharmaceuticals U.S.A., Inc.$533K
- ADC Therapeutics America, Inc.$478K
- Amgen$384K
- Incyte Corporation$312K
- plus $549K from 10 others
What the payments were for
- Consulting fees$91,51381%
- Speaking & faculty fees$15,36814%
- Travel & lodging$3,7253%
- Food & beverage$2,7622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 12 | $17,939 |
| Genentech, Inc. | 3 | $14,100 |
| ADC Therapeutics America, Inc. | 17 | $12,393 |
| Gilead | 4 | $11,140 |
| Novartis | 5 | $8,755 |
| Amgen | 4 | $6,182 |
| Sobi, Inc | 1 | $5,550 |
| Verastem, Inc. | 6 | $5,296 |
| Genentech USA, Inc. | 5 | $5,056 |
| Bristol Myers Squibb | 7 | $4,215 |
| Swedish Orphan Biovitrum AB | 1 | $3,623 |
| Eli Lilly | 1 | $3,600 |
| Epizyme, Inc. | 2 | $3,575 |
| AbbVie | 2 | $2,665 |
| Incyte Corporation | 2 | $2,500 |
| Beigene USA, Inc. | 3 | $1,774 |
| Recordati_rare_diseases_inc. | 1 | $1,103 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| Bayer | 1 | $900 |
| Pfizer | 1 | $810 |
| Seagen Inc. | 7 | $564 |
| Beigene, Ltd. | 1 | $450 |
| Genmab U.S., Inc. | 2 | $136 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Roche Products Limited | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,367 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 110 | $1,514,611 |
| ImbruvicaIbrutinib | 42 | $815,101 |
| VenclextaVenetoclax | 30 | $541,226 |
| JaypircaPirtobrutinib | 14 | $255,009 |
| XareltoRivaroxaban | 15 | $7,963 |
| Acyclovir | 117 | $1,659 |
| Gabapentin | 30 | $509 |
| Famotidine | 15 | $259 |
| Oxycodone Hcl | 11 | $157 |
| Dexamethasone | 12 | $156 |
| Prochlorperazine Maleate | 11 | $114 |
| Allopurinol | 15 | $90 |
| Prednisone | 49 | $83 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $76 |
| Ondansetron Hcl | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $1,774 | $1,514,611110 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $815,10142 claims |
| AbbVieVenclexta | $2,665 | $541,22630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.